Cart
sales@molnova.com
Aurora B inhibitor 1
CAS No. 937276-52-3
Aurora B inhibitor 1( —— )
Catalog No. M33019 CAS No. 937276-52-3
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 μM) with potential anticancer activity for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1064 | Get Quote |
|
| 5MG | 1710 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAurora B inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionAurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 μM) with potential anticancer activity for cancer research.
-
DescriptionAurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
-
In VitroAurora B inhibitor 1 also inhibits JAK3 and JAK2 with Kis of <0.25 μM and <0.10 μM, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAurora Kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number937276-52-3
-
Formula Weight529.97
-
Molecular FormulaC25H26ClF2N7O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC1(CN(C1)C2=NC(O[C@@H]3CN(C(=O)C4=C(F)C=CC(Cl)=C4)CC3)=NC(NC5=NNC(C)=C5)=C2)C6CC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. FRAYSSE, Damien, et al. AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS. WO2007059299A1.
molnova catalog
related products
-
Alisertib
A potent and highly selective inhibitor of Aurora A with IC50 of 1.2 nM; has less activity against Aurora B (IC50=396.5 nM) and a 205-kinase panel.
-
BPR1K653
BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively.
-
AKI-603
A novel small molecule Aurora A kinase inhibitor with IC50 of 12.3 nM, also inhibits Aurora B kinase activity to a less extent.
